View Poster: ERK1/2 Inhibition Overcomes Resistance in Acute Myeloid Leukemia (AML) and Alters Mitochondrial Dynamics Abstract: Background: Presence at diagnosis or acquisition of activating RAS pathway mutations is a pervasive mechanism of resistance to therapy in AML. Efforts to directly target mutant RAS have been unsuccessful and the efficacy of BRAF and MEK inhibitors has […]
About Renee Hansen
This author has not written his bio yet.
But we are proud to say that Renee Hansen contributed 62 entries already.
Entries by Renee Hansen
View Poster: Treatment with the dual mechanism ERK inhibitor, ASTX029, alters myeloid cell differentiation Abstract: The inhibition of aberrant MAPK pathway activity is a clinically validated approach which has resulted in the approval of agents targeting tumors driven by activating mutations in BRAF and KRAS. Although the overall response rate to MAPK-targeting agents is high, […]
View Poster: Efficacy of Oral Decitabine/Cedazuridine (ASTX727) in the CMML Subgroup from the ASCERTAIN Phase 3 Study Abstract: Background/Introduction: Chronic Myelomonocytic Leukemia (CMML) is an uncommon MDS/MPN overlap syndrome that has historically been included under the umbrella of myelodysplastic syndromes (MDS) for clinical trial and treatment. As a result, DNA methyltransferase inhibitors (DNMTi) such as […]
View Poster: Combining the IAP Antagonist Tolinapant with a DNA Hypomethylating Agent Enhances Immunogenic Cell Death in Preclinical Models of T-Cell Lymphoma Abstract: Introduction: Tolinapant is a potent, non-peptidomimetic antagonist of cIAP1, cIAP2 and XIAP. In ongoing Phase 2 trial (NCT02503423), tolinapant has shown activity against highly pre-treated peripheral and cutaneous T-cell lymphoma (Samaniego et […]
View Poster Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 302 Patients with Relapsed or Refractory (r/r) Acute Myeloid Leukemia after Intensive Chemotherapy (ASTRAL-2 Study) Abstract: Background: Guadecitabine (G) is a next generation subcutaneous (SC) hypomethylating agent (HMA) resistant to degradation by cytidine deaminase which results in […]
View Poster Oral decitabine/cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: a Longer-Term Follow-Up of from the ASCERTAIN Study Abstract: Background/Introduction: Lower-risk (IPSS low risk and Int-1) myelodysplastic syndromes (MDS) are typically treated supportively to address cytopenias. DNA methyltransferase inhibitors (DNMTi) such as azacitidine and decitabine (DEC) are FDA-approved for higher risk MDS patients (pts), […]
View Poster: A Phase 1 Study Evaluating ASTX727 (decitabine and cedazuridine) and Venetoclax in Combination Therapy in Newly Diagnosed AML Patients Unfit for Intensive Induction Chemotherapy Abstract: Introduction: The combination of a DNA methyltransferase inhibitor (DNMTi; parenteral azacitidine or decitabine) with the BCL2 inhibitor venetoclax is a newly established standard-of-care regimen for patients with newly diagnosed […]
Blood Advances. 2021 Oct 26;5(20):4003-4016. DOI: 10.1182/bloodadvances.2020003955
View Poster Prolonged survival observed in 133 MDS patients treated with oral decitabine/cedazuridine Abstract: Background and aims DNMTi are active in MDS treatment, however chronic parenteral therapy constitutes a burden for these patients, often elderly with co-morbid conditions. Oral decitabine(35 mg)/cedazuridine(100mg) given Days 1-5 every 28 days produces equivalent pharmacokinetic exposure (AUV) to 20 mg/m2 […]
View Poster: Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) Abstract: Aim: Confirm fixed dose combination (FDC) of oral decitabine/cedazuridine produces similar clinical activity vs. IV decitabine. Background: An oral FDC of 35 mg decitabine and 100 mg of CDA inhibitor cedazuridine has shown […]